BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 12228849)

  • 21. Pleiotropic effects of statins and related pharmacological experimental approaches.
    Alegret M; Silvestre JS
    Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
    Sever PS
    Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy.
    Tamargo J; Caballero R; Gómez R; Núñez L; Vaquero M; Delpón E
    Pharmacol Ther; 2007 Apr; 114(1):107-26. PubMed ID: 17287023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
    Weber MA; Giles TD
    Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenomics of cholesterol-lowering therapy.
    Schmitz G; Langmann T
    Vascul Pharmacol; 2006 Feb; 44(2):75-89. PubMed ID: 16337220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statins effect on smooth muscle cell proliferation.
    Bellosta S; Arnaboldi L; Gerosa L; Canavesi M; Parente R; Baetta R; Paoletti R; Corsini A
    Semin Vasc Med; 2004 Nov; 4(4):347-56. PubMed ID: 15861311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcium channel blockers, endothelial dysfunction, and combination therapy.
    Schulman IH; Zachariah M; Raij L
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):40-5. PubMed ID: 16640172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What do the statins tell us?
    LaRosa JC
    Am Heart J; 2002 Dec; 144(6 Suppl):S21-6. PubMed ID: 12486412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk.
    Ginsberg HN; Stalenhoef AF
    J Cardiovasc Risk; 2003 Apr; 10(2):121-8. PubMed ID: 12668909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin resistance and the endothelium.
    Hsueh WA; Lyon CJ; Quiñones MJ
    Am J Med; 2004 Jul; 117(2):109-17. PubMed ID: 15234647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Bocan TM
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.
    Rosenson RS
    Curr Probl Cardiol; 2005 May; 30(5):241-79. PubMed ID: 15829899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The pleiotropic effects of statins].
    Wolfovitz E
    Harefuah; 2005 Aug; 144(8):577-82, 597. PubMed ID: 16146158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
    Ray KK; Cannon CP; Ganz P
    Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.